All In Biotech

Drug Trial Radar · NCT06926660

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

A Phase II Randomised, Double-blind, Parallel-group, Multicentre, International Trial to Investigate the Safety and Efficacy of Vicadrostat and Empagliflozin Administered With Simultaneous vs Staggered Initiation in Participants With Chronic Kidney Disease at Risk of Kidney Disease Progression

Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 492 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

492

Actual

Start

Jul 18, 2025

Primary completion

Aug 14, 2026

Study completion Aug 14, 2026

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Apr 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with chronic kidney disease (CKD) that is at risk of getting worse. People who have taken a specific type of medication for kidney disease called SGLT2 inhibitor within 1 month before the study or have certain health conditions cannot take part in this study. The purpose of this study is to find out whether a medicine called vicadrostat, used in combination with another medicine called empagliflozin, works in people with chronic kidney disease. In this study, participants are randomly assigned to one of two groups. Participants have an equal chance of being assigned to either group. In one group, participants take the 2 study medicines, vicadrostat and empagliflozin, every day for 3 months. In the other group, participants take placebo and empagliflozin for the first 1.5 months, and then they take vicadrostat and empagliflozin together for the next 1.5 months. The study medicines are taken orally as tablets. Placebo tablets look like vicadrostat tablets but do not contain any medicine. Participants are in the study for about 4.5 months. During this time, they visit the study site multiple times. Doctors regularly test kidney function by measuring specific proteins in the blood and urine. The results are compared between the two groups to see whether there are differences between starting the study medicines at the same time or one after the other. The doctors also regularly check participants' health and take note of any unwanted effects.

Conditions

  • Chronic Kidney Disease

Interventions

  • VicadrostatDrug

    Vicadrostat

  • EmpagliflozinDrug

    Empagliflozin

  • Placebo matching vicadrostatDrug

    Placebo matching vicadrostat

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute change in estimated glomerular filtration rate (eGFR) (mL/min/1.73m2) from baseline to Week 14 and week 16Time frame: At baseline, up to week 16

Locations

157 sites in 24 countries. Site status is shown where the registry gives one.

  • Apogee Clinical Research

    Huntsville, Alabama

  • Orange County Clinical Trials

    Anaheim, California

  • North America Research Institute

    San Dimas, California

  • Valiance Clinical Research-Tarzana-68237

    Tarzana, California

  • Amicis Research Center - Valencia

    Valencia, California

  • Focus Clinical Research

    West Hills, California

  • Clinical Research of Brandon LLC

    Brandon, Florida

  • Hillcrest Medical Research

    DeLand, Florida

  • Encore Medical Research

    Hollywood, Florida

  • Finlay Medical Research Corp

    Miami, Florida

  • Total Research Group, LLC

    Miami, Florida

  • San Marcus Research Clinic, Inc.

    Miami Lakes, Florida

  • West Orange Endocrinology, PA

    Ocoee, Florida

  • Florida Kidney Physicians - Riverview/Brandon

    Riverview, Florida

  • Masters of Clinical Research, Inc

    Augusta, Georgia

  • Boise Kidney and Hypertension, PLLC

    Boise, Idaho

  • Research by Design, LLC

    Chicago, Illinois

  • Nephrology Associates of Northern Illinois and Indiana - Oak Brook

    Hinsdale, Illinois

  • Nephrology Associates of Northern Illinois and Indiana - Fort Wayne

    Fort Wayne, Indiana

  • Kansas Nephrology Research Institute, LLC

    Wichita, Kansas

  • Northwest Louisiana Nephrology

    Shreveport, Louisiana

  • Aa Mrc Llc

    Flint, Michigan

  • Michigan Kidney Consultants

    Pontiac, Michigan

  • Elixia MNA, LLC

    City of Saint Peters, Missouri

  • Healor Primary Care

    Las Vegas, Nevada

  • Endocrine Associates of Long Island

    Smithtown, New York

  • Durham Nephrology Associates

    Durham, North Carolina

  • Lucas Research, Inc.

    Morehead City, North Carolina

  • Brookview Hills Research Associates LLC

    Winston-Salem, North Carolina

  • Heritage Valley Medical Group

    Beaver, Pennsylvania

  • Southeast Renal Research Institute

    Chattanooga, Tennessee

  • Arlington Nephrology

    Arlington, Texas

  • Endocrine Associates

    Houston, Texas

  • Clinical Advancement Center, PLLC

    San Antonio, Texas

  • Javara Inc.-Stephenville-68996

    Stephenville, Texas

  • Utah Kidney Research Institute

    Salt Lake City, Utah

  • Tidewater Physicians Multispecialty Group

    Newport News, Virginia

  • IDIM - Instituto de Diagnostico e Investigaciones Metabolicas

    Buenos Aires, Argentina

  • CEDIC - Centro de Investigacion Clinica

    CABA, Argentina

  • Mautalen- Salud e Investigacion

    CABA, Argentina

Showing 40 of 157 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.